This morning we called on Public Health England (PHE) to introduce a more accurate and simpler bowel cancer screening test, called the Faecal Immunochemical Test (FIT), to help increase uptake and detection of the disease.
Today we have written, alongside Bowel Cancer UK, to the Chief Executive of Public Health England (PHE), the body responsible for the 'Be Clear on Cancer' campaign.
In the letter, we ask for PHE to repeat the successful 'Be Clear on Bowel Cancer' symptoms awareness campaign.
Mr Duncan Selbie
Public Health England
Dear Mr Selbie
Be Clear on Bowel Cancer campaign
Wide variations and poor uptake of bowel cancer screening is leading to late cancer diagnosis and preventable deaths, says Beating Bowel Cancer.
New figures, released by the charity, have revealed a 24% difference between the highest and lowest areas of uptake for bowel cancer screening across England. The percentages vary from 66% in the highest performing area to 42% in the lowest1.
If you’re a football fan lookout this weekend for the Know the Score campaign, which aims to raise awareness of bowel cancer through football. At Beating Bowel Cancer we’re thrilled to be part of the Know the Score campaign which kicks off on 12 April. Started in 2011, the campaign brings together a number of charities to raise awareness of the disease.
New figures released today from Public Health England (PHE) show that nearly 37 per cent (36.6%) of bowel scope screening centres in England are operational, exceeding the 30% roll out target, set by the Department of Health.
Bowel scope screening, also known as flexible sigmoidoscopy, is a one-off test offered to men and women at the age of 55.This type of screening examines the lower part of the bowel – the part where most bowel cancers are found. The aim is to find any small growths called polyps which may develop into bowel cancer if left untreated.
Many of the newspapers cover the proposals being announced today by the National Institute for Health and Care Excellence (NICE) about the way it decides which medicines the NHS should fund in England and Wales.
NICE has been asked to change its funding formulas to ensure the NHS gets value for money on the drugs it funds.
Newspapers like the Daily Telegraph highlight concerns that cancer patients could be denied life-extending treatments.
Today the National Institute for Health and Care Excellence (NICE) has rejected the use of afilbercept (Zaltrap) on the NHS in England and Wales.
Afilbercept is used for patients with bowel cancer in advanced stages when it has spread to other organs.
Mark Flannagan, Chief Executive of the charity Beating Bowel Cancer, said: “We are disappointed by NICE’s decision, as patients with advanced bowel cancer currently have very few options open to them for treatment that could prolong their lives.
Everton legend Kevin Sheedy has been announced as an Ambassador for the charity Beating Bowel Cancer.
Kevin was diagnosed with bowel cancer in 2012 and both his parents have been affected by the disease. Following treatment, Kevin was given the all-clear and is now helping to raise awareness of bowel cancer.
Got a question about your bowels that you’re just too embarrassed to ask? Tell us!
We know that many people suffer in silence because they are too embarrassed to talk about their poo, and yet constipation and other bowel worries affect millions of people. We want the nation to be more open and willing to talk about their poo and to discuss health concerns as soon as they appear. So we have teamed up with constipation brand Dulcolax to help answer people’s bowel health questions and get people talking.
The Scottish Medicines Consortium (SMC) has announced that a treatment called afilbercept (Zaltrap) is to be made available for use on the NHS in Scotland.
This treatment is used in conjunction with chemotherapy for patients whose bowel cancer has spread to other parts of the body.
Bowel cancer is the third most common cancer in Scotland with almost 4,000 people diagnosed each year. Future projections of the prevalence of bowel cancer in Scotland suggest there will be a 20% increase in the number of people getting the disease between 2013 and 2017.